- Home
- HURN vs AMPH Comparison
HURN vs AMPH Comparison
Compare HURN & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- AMPH
- Stock Information
- Founded
- HURN 2002
- AMPH 1996
- Country
- HURN United States
- AMPH United States
- Employees
- HURN N/A
- AMPH N/A
- Industry
- HURN Professional Services
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- AMPH Health Care
- Exchange
- HURN Nasdaq
- AMPH Nasdaq
- Market Cap
- HURN N/A
- AMPH 2.5B
- IPO Year
- HURN 2004
- AMPH 2014
- Fundamental
- Price
- HURN $115.91
- AMPH $51.45
- Analyst Decision
- HURN Strong Buy
- AMPH Buy
- Analyst Count
- HURN 4
- AMPH 4
- Target Price
- HURN $131.75
- AMPH $63.00
- AVG Volume (30 Days)
- HURN 66.1K
- AMPH 268.7K
- Earning Date
- HURN 10-29-2024
- AMPH 11-06-2024
- Dividend Yield
- HURN N/A
- AMPH N/A
- EPS Growth
- HURN 14.29
- AMPH 62.07
- EPS
- HURN 4.16
- AMPH 3.15
- Revenue
- HURN $1,425,021,000.00
- AMPH $712,891,000.00
- Revenue This Year
- HURN $11.16
- AMPH $18.04
- Revenue Next Year
- HURN $8.65
- AMPH $4.41
- P/E Ratio
- HURN $25.27
- AMPH $16.26
- Revenue Growth
- HURN 12.76
- AMPH 31.80
- 52 Week Low
- HURN $84.26
- AMPH $36.56
- 52 Week High
- HURN $115.65
- AMPH $65.92
- Technical
- Relative Strength Index (RSI)
- HURN 66.87
- AMPH 59.40
- Support Level
- HURN $103.24
- AMPH $49.38
- Resistance Level
- HURN $108.75
- AMPH $51.84
- Average True Range (ATR)
- HURN 2.06
- AMPH 1.25
- MACD
- HURN 0.22
- AMPH 0.10
- Stochastic Oscillator
- HURN 100.00
- AMPH 78.90
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.